Collaborating selectively is an important part of our business strategy. We are especially interested in collaborating with companies with particular expertise in therapeutic areas synergistic with our science and product pipeline to realize its full potential. If you are interested in discussing how we may work together to our mutual benefit, please contact Albireo Business Development.
EA Pharma Co., Ltd. (Eisai/Ajinomoto)
License Agreement for elobixibat for gastrointestinal disorders in Japan and other select countries in Asia (not China)